There has been a shift in the treatment paradigm for relapsed/refractory (R/R) multiple myeloma (MM) over the last decade due to the emergence of novel drugs and combination regimens. At the recent American Society of Hematology (ASH) Annual Meeting 2019,

Multiple myeloma (MM) is a type of clonal neoplasm with substantial morbidity and mortality. With the development of better therapies, MM has transformed from untreatable to still incurable but treatable.¹

Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies.¹ In Hong Kong, the majority of MM patients are older than 65-years-old. Management of these patients needs special consideration due to age-related comorbidities.

In the recent DREAMM-2 study, single-agent belantamab mafodotin-blmf has demonstrated anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.¹ Based on this result, the United